The integration of targeted agents into systemic therapy of metastatic colorectal cancer

Annals of Oncology

Volumn 17, Issue SUPPL. 10, 2006, Pages

  Arnold, D ^a   Siewczynski, R ^a   Schmoll, H J ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PELITINIB; SORAFENIB; SUNITINIB; UFT; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VATALANIB;

ANGIOGENESIS; ARTERY EMBOLISM; ARTERY THROMBOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG CHOICE; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG TARGETING; FOLLICULITIS; HUMAN; HYPERTENSION; LUNG EMBOLISM; META ANALYSIS; METASTASIS; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TREATMENT PLANNING; TUMOR BLEEDING; TUMOR VASCULARIZATION; VEIN THROMBOSIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; HUMANS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33749602960     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl249     Document Type: Article

References (52)

1. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
2. Douillard A Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial, Lancet 2000; 355: 1047-1047.
3. Koehne C, Van Cutsem E, Wils J et al. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: Results of EORTC G1-group study 40986. Proc Am Soc Clin Oncol 2003; 22: 254a.
4. De Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without Oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
5. Grothey A, Deschler B, Kroening H et al. Phase II study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) versus weeldy high-dose 24h 5-FU infusion/FA + Oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002; 21: 129a.
6. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucavorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-147.
7. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23.
8. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004 Apr 1; 22 (7): 1209-14.
9. Folkman J et al. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1996; 1: 27.
10. Folkman J, Cole P, Zimmerman S. Tumor behavior in isolated perfused organs: In vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg. 1966: 164: 491.
11. Ferrara N, Carver-Moore K, Chen H et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380: 439.
12. Verheul HM, Pinedo HM. Vascular endothelial growth factor and its inhibitors. Drugs Today (Barc) 2003; 39 (suppl C); 81-93.
13. Choi HJ, Hyun MS, Jung GF et al. Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence, Oncology 1998; 55: 575-581.
14. Ellis L et al. Angiogenesis and its role in colorectal tumor and metastasis formation. Semin Oncol 2004; 31 (6 suppl 17): 3-9.
15. Warren RS, Yuan H, Matli MR et al. Regulation by vascular endothelial growth factor of human colon cancer tumorgenesis in a mouse model of experimental fiver metastasis. J Clin Invest 1995; 95: 1789-1797.
16. Rosen LS. et al, Inhibitors of the vascular endothelial growth factor receptor Hematol Oncol Clin North Am 2002; 16: 1173-1187.
17. Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-850.
18. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2003; 350: 2335-2342.
19. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizurnab plus fluorouracil (FU)/leucovorin (LV)with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65.
20. Kabbinavar FF, Schulz J, McCleod M et al. Bevacizumab (a moniclonal antibody to vascular endothellal growth factor) to prolong progression-free, survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CPT-11. Proc Am Soc Clin Oncol 2004; 23; 24: 249a.
21. Hochster HS, Hart LL, Ramanthan RK et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study. Proc Am Soc Clin Oncol 2006; 24: 148s (Abstr 3510).
22. Giantonio BJ, Catalano PJ, Meropol NJ et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc Am Soc Clin Oncol 2005; 23: Abstr 2.
23. Berry SR, Cunningham D, Michael M et al. Preliminary safety of bevacizumab with first-line Folfox, Capox, Folfiri and capecitabine for mCRC-First B.E.A.Trial. Proc Am Soc Clin Oncol 2006; 24: 154s (Abstr 3534).
24. Kozloff M, Hainsworth J, Badarinath S et al. Efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE. Proc Am Soc Clin Oncol 2006; 24: 155s (Abstr 3537).
25. Gruenberger T, Gruenberger B, Schelthauer W et al. Neoadjuvant therapy with bevacizumab. J Clin Oncol 2006; 24(16): 2592-3; author reply 2593-4.
26. Hecht A Trarbach T, Jaeger E et al. A randomized, double-blind, placebo-controlled phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin (5-fluorouracil-leucovorin and PTK787/ZK222584 or placebo (CONFORM-1). Proc Am Soc Clin Oncol 2005; 23.
27. Koehne C et al. Results of an interim analysis of a multinational randomized, double-blind, phase III study In patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2). Proc Am Soc Clin Oncol 2006; 24: 148s (Abstr 3508).
28. Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem. 1987; 56: 881-914.
29. Rodeck U, Herlyn M, Herlyn D et al. Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: immunologically mediated and effector cell-independent effects. Cancer Res. 1987; 47: 3692-3696.
30. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19: 6550-6565.
31. Saltz LB, Meropol NJ, Loehrer PJ et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208.
32. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
33. Lenz HJ, Mayer RJ, Gold PJ et al. Activity, of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proc Am Soc Clin Oncol 2004; 22: Abstr 3510.
34. Peeters M et al. A phase 3, multicenter, randomized controlled trial (RCT) of panitumumab plus best supportive care (BSC) versus BSC alone in patients (pts) with Metastatic colorectal cancer (mCRC). Am Assoc Cancer Res Annual Meeting 2006.
35. Prewett MC, Hooper AT, Bassi R et al. Enhanced Antitumor Activity of Anti-epidermal Growth Factor Receptor Monoclonal Antibody IMC-C225 in Combination with Irinotecan (CPT-11) against Human Colorectal Tumor Xenografts. Clin Cancer Res 2002 8: 994-1003.
36. Saltz L, Lenz H, Hochster H et al. Randomized Phase II Trial of Cetuximab/Bevacizumab/Irinotecan (CBI) versus Cetuximab/Bevacizumab (CB) in Irinotecan-Refractory Colorectal Cancer Proc Am Soc Clin Oncol 2005; 23; Abstr 3508.
37. Rougler P et al. Cotuximab+FOLFIRI as first-line treatment for metastatic colorectal cancer. Proc Am Soc Clin Oncol 2004; 22: Abstr 3513.
38. Rosenberg AH, Loehrer PJ, Needle MN et al. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr). Proc Am Soc Clin Oncoll 2002; 21; Abstr 536.
39. Folprecht G. Lutz MP, Schöffski P et al. Cetuximab and irinotecan/ 5-fluorouracil/follnic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006; 17: 450-456.
40. Seufferlein T, Arnold D et al, A phase VII study of cetuximab in combination with 5-fluorouracil (5-FU/folinic acid (FA) plus weekly oxaliplatin (L-DHP) (FUFOX) in the first-line treatment of patients with metastatic colorectall cancer (mCRC) expressing epidermal growth factor receptor (EGFR). Preliminary results. Proc Am Soc Clin Oncol 2005; 23; Abstr 3644.
41. Diaz-Rubio E et al. Cetuximab in combination with oxaliplatin/ 5-fluorouracil (5-FU/folinic acid (FA) (FOLFOX-4) in the first-line treatmerrt of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study. Proc Am Soc Clin Oncol 2005; 23: Abstr 3535.
42. Venook A, Niedzwiecki D, Hollis D et al. Phase III study of Irinotecan/ 5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX)±cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. Proc Am Soc Clin Oncol 2006; 24: 148s (abstract 3509).
43. Jennis A, Polikoff J, Mitchell E et al. Erbitux (Cetuximab) Plus FOLFOX for Colorectal Cancer (EXPLORE): Preliminary efficacy analysis of a randomized phase III trial. Proc Am Soc Clin Oncol 2005; 23: Abstr 3574.
44. Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-1810.
45. Pippas AW, Lenz HJ, Mayer RJ et al. Analysis of EGFR Status in Metastatic Colorectal Cancer Patients Treated with Cetuximab Monotherapy. Proc Am Soc Clin Oncol 2005; 23: Abstr 3595.
46. Niederle N, et al. Erlotinib as single agent in 2nd and 3rd line treatment in patients with metastatic colorectal cancer. Results of a two-cohort multicenter phase II trial European Journal of Cancer Supplements Volume 3, No. 2, October 2005, Page 184.
47. Arnold D, Peinert S, Voigt W et al. Epidermal growth factor receptor tyrosine kinase inhibitors: Present and future role in gastrointestinal cancer treatment. Oncologist 2006; 11: 602-611.
48. Meyerhardt JA, Stuart K, Zhu A et al. Phase II study of FOLFOX, bevacizumab and erlotinib as initial therapy for patients with metastatic oolorectal cancer (MCRC). Proc Am Soc Clin Oncol 2006; 24: 157s (Abstr 3545).
49. Baselga J, Schöffski P, Rojo F et al. A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC) and non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2006; 24: 122s (Abstr 3006).
50. Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg 2004; 240: 644-657.
51. Hecht R, Mitchell E, Barada J et al. Panitumumab antitumor activity in patients with metastatic colorectal cancer (MCRC) expressing low (1-9%) or negative (<1%) levels of epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2006; 24: 157s (Abstr 3547).
52. Folprecht G, Grothey A, Alberts S et al. Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates. Ann Oncol 2005; 16: 1311-1319.